Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SI-B001 + SI-B003
- Development stage
- Unknown
- Lead developer
- Biokin Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SI-B001 + SI-B003 is a combination of two investigational bispecific monoclonal antibodies for the treatment of advanced or metastatic solid tumors, particularly non-small cell lung cancer (NSCLC). SI-B001 (izalontamab) is a tetravalent bispecific antibody that targets the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 3 (HER3), inhibiting their oncogenic signaling and engaging immune effector mechanisms. SI-B003 (danvilostomig) is a tetravalent bispecific antibody targeting the immune checkpoints PD-1 and CTLA-4, restoring anti-tumor T cell activity through checkpoint blockade. Both antibodies are designed to work synergistically—SI-B001 directly targets tumor cell growth pathways, while SI-B003 enhances immune-mediated tumor destruction. The combination is in clinical development for patients with locally advanced or metastatic NSCLC who have failed prior therapies.[1][3][5][7]
- Other names
- izalontamabdanvilostomig
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on SI-B001 + SI-B003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SI-B001 + SI-B003.